HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294.

Abstract
V11294 is a new cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor of the rolipram class. In this report we present the pharmacological profile of V11294. V11294 inhibited PDE4 isolated from human lung with IC(50) 405 nM, compared to 3700 nM for rolipram. In contrast, V11294 inhibition of human PDE3 and PDE5 occurred only at concentrations greater than 100,000 nM. Like rolipram, V11294 inhibited PDE4D more potently than other PDE4 subtypes. V11294, when incubated with human anticoagulated whole blood in vitro, or administered to mice, caused increased cAMP concentration, consistent with inhibition of PDE4. V11294 inhibited lectin-induced proliferation and lipopolysaccharide-induced TNFalpha synthesis by human adherent monocytes in vitro and inhibited lipopolysaccharide-induced TNFalpha synthesis in mice. V11294 caused relaxation of guinea pig isolated trachea and inhibited allergen-induced bronchoconstriction and eosinophilia in guinea pigs at doses of 1 and 3 mg/kg, p.o. In ferrets, V11294 was not emetogenic at doses up to 30 mg/kg, p.o., despite plasma concentration reaching 10-fold the IC(50) for PDE4. In contrast, rolipram induced severe retching and vomiting at 10 mg/kg, p.o. In conclusion, V11294 is an orally active PDE4 inhibitor that exhibits antiinflammatory activity in vitro, and in vivo at doses that are not emetogenic.
AuthorsDonna D Gale, Peter Hofer, Domenico Spina, Esther A Seeds, Katherine H Banner, Selina Harrison, Gary Douglas, Tatsui Matsumoto, Clive P Page, Richard H Wong, Stephan Jordan, Forrest Smith, Nandini Banik, Perry V Halushka, David Cavalla, Yakov Rotshteyn, Donald J Kyle, Ronald M Burch, Mark Chasin
JournalPulmonary pharmacology & therapeutics (Pulm Pharmacol Ther) Vol. 16 Issue 2 Pg. 97-104 ( 2003) ISSN: 1094-5539 [Print] England
PMID12670778 (Publication Type: Journal Article, Review)
CopyrightCopyright 2003 Elsevier Science Ltd.
Chemical References
  • 3-(3-cyclopentyloxy-4-methoxybenzyl)-6-ethylamino-8-isopropyl-3H-purine
  • Phosphodiesterase Inhibitors
  • Purines
  • 3',5'-Cyclic-AMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 3
  • Cyclic Nucleotide Phosphodiesterases, Type 4
  • PDE4D protein, human
  • Rolipram
Topics
  • 3',5'-Cyclic-AMP Phosphodiesterases (antagonists & inhibitors, isolation & purification)
  • Animals
  • Cyclic Nucleotide Phosphodiesterases, Type 3
  • Cyclic Nucleotide Phosphodiesterases, Type 4
  • Humans
  • Phosphodiesterase Inhibitors (adverse effects, blood, metabolism)
  • Purines (blood, metabolism, pharmacology)
  • Rolipram (adverse effects, blood, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: